- Home
- JBI vs CVAC Comparison
JBI vs CVAC Comparison
Compare JBI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBI
- CVAC
- Stock Information
- Founded
- JBI 2002
- CVAC 2000
- Country
- JBI United States
- CVAC Germany
- Employees
- JBI N/A
- CVAC N/A
- Industry
- JBI Building Products
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- JBI Industrials
- CVAC Health Care
- Exchange
- JBI Nasdaq
- CVAC Nasdaq
- Market Cap
- JBI 1.2B
- CVAC 1.2B
- IPO Year
- JBI N/A
- CVAC 2020
- Fundamental
- Price
- JBI $10.40
- CVAC $5.48
- Analyst Decision
- JBI Buy
- CVAC Hold
- Analyst Count
- JBI 6
- CVAC 3
- Target Price
- JBI $10.70
- CVAC $6.83
- AVG Volume (30 Days)
- JBI 1.2M
- CVAC 789.9K
- Earning Date
- JBI 08-07-2025
- CVAC 08-18-2025
- Dividend Yield
- JBI N/A
- CVAC N/A
- EPS Growth
- JBI N/A
- CVAC N/A
- EPS
- JBI 0.30
- CVAC 0.87
- Revenue
- JBI $899,500,000.00
- CVAC $566,039,775.00
- Revenue This Year
- JBI N/A
- CVAC N/A
- Revenue Next Year
- JBI $5.69
- CVAC $24.04
- P/E Ratio
- JBI $34.22
- CVAC $6.35
- Revenue Growth
- JBI N/A
- CVAC 787.60
- 52 Week Low
- JBI $5.99
- CVAC $2.37
- 52 Week High
- JBI $11.49
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- JBI 73.27
- CVAC 60.60
- Support Level
- JBI $8.57
- CVAC $5.41
- Resistance Level
- JBI $10.70
- CVAC $5.54
- Average True Range (ATR)
- JBI 0.39
- CVAC 0.05
- MACD
- JBI 0.17
- CVAC -0.01
- Stochastic Oscillator
- JBI 93.75
- CVAC 73.68
About JBI Janus International Group Inc.
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.